US Patent No: 8,092,831 - Analytics, PDF, Full Text and PAIR Access

Number of patents in Portfolio can not be more than 2000

Antihistamine and decongestant system

ALSO PUBLISHED AS: 20040091533

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to an oral pharmaceutical formulation that employs: (1) a compressed core containing a decongestant or pharmaceutically acceptable salt thereof; (2) a delayed release coating on the compressed core and (3) immediate release therapeutic amounts of a decongestant and an antihistamine.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ANDRX PHARMACEUTICALS, INC.DAVIE, FL60

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kositprapa, Unchalee Davie, FL 29 144
Sriwongjanya, Mongkol Davie, FL 11 20

Cited Art Landscape

Patent Info (Count) # Cites Year
 
MCNEIL-PPC, INC. (19)
5,004,613 Oral sustained release pharmaceutical formulation and process 38 1989
5,073,380 Oral sustained release pharmaceutical formulation and process 35 1990
5,215,755 Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets 43 1991
5,658,589 Subcoated simulated capsule-like medicament 33 1991
5,405,617 Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals 17 1991
5,272,137 Aqueous pharmaceutical suspension for pharmaceutical actives 49 1992
5,429,825 Rotomelt granulation 38 1992
5,296,233 Dual subcoated simulated capsule-like medicament 25 1992
5,451,409 Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends 35 1993
5,489,436 Taste mask coatings for preparation of chewable pharmaceutical tablets 86 1993
5,409,907 Aqueous pharmaceutical suspension for pharmaceutical actives 47 1993
5,529,783 Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan 16 1994
5,681,577 Multiple action cold/sinus preparations 19 1995
5,919,481 Fill material for soft gelatin pharmaceutical dosage form 9 1996
5,658,919 Aqueous pharmaceutical suspension and process for preparation thereof 25 1996
5,916,590 Soft gelatin pharmaceutical dosage form 11 1996
5,876,759 Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof 51 1997
5,840,337 Gelling agent for polyethylene gylcol 5 1997
5,891,476 Tastemasked pharmaceutical system 16 1997
 
SCHERING CORPORATION (8)
4,282,233 Antihistaminic 11-(4-piperidylidene)-5H-benzo-[5,6]-cyclohepta-[1,2-b]-pyridines 102 1980
4,695,591 Controlled release dosage forms comprising hydroxypropylmethylcellulose 45 1985
4,659,716 Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines 56 1986
4,999,189 Sustained release oral suspensions 33 1988
4,990,535 Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine 53 1989
5,100,675 Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine 52 1990
5,869,479 Treatment of upper airway allergic responses 58 1997
6,114,346 Treating sleep disorders using desloratadine 14 1999
 
The Procter & Gamble Company (8)
5,431,916 Pharmaceutical compositions and process of manufacture thereof 48 1993
5,510,389 Concentrated acetaminophen solution compositions 4 1994
5,827,852 Coated pharmaceutical compositions 22 1994
5,458,879 Oral vehicle compositions 72 1994
5,560,913 Pharmaceutical compositions 13 1995
5,641,512 Soft gelatin capsule compositions 29 1995
5,560,921 Chewable decongestant compositions 3 1995
5,648,358 Compositions and methods for treating respiratory disorders 6 1996
 
Analgesic Associates (5)
4,749,711 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs 16 1987
4,749,721 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs 17 1987
4,749,722 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs 19 1987
4,839,354 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs 17 1987
5,025,019 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs 17 1989
 
ALZA CORPORATION (4)
4,801,461 Pseudoephedrine dosage form 35 1987
4,915,952 Composition comprising drug, HPC, HPMC and PEO 17 1989
4,915,953 Dosage form for delivering acetaminophen or phenylpropanolamine 47 1989
5,023,076 Lamina comprising carboxyvinyl polymer 6 1990
 
WYETH (4)
5,024,997 Palatable ibuprofen solutions 16 1990
5,616,621 Taste masking liquids 10 1995
5,602,182 Taste masking pseudoephedrine HCL containing liquids 10 1995
5,759,579 Pharmaceutical suspension systems 47 1996
 
Warner-Lambert Company (3)
4,632,821 Magnesium trisilicate suitable for preparation of medicament adsorbates of decongestants 19 1985
4,758,424 Medicament adsorbates of decongestants with complex magnesium aluminum silicate and their preparation 39 1987
5,385,941 Salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms 10 1993
 
ANDRX PHARMACEUTICALS, INC. (2)
5,654,005 Controlled release formulation having a preformed passageway 44 1995
5,922,352 Once daily calcium channel blocker tablet having a delayed release core 18 1997
 
AVENTIS INC. (2)
4,999,226 Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination 22 1989
4,996,061 Pharmaceutical composition for piperidinoalkanol-decongestant combination 36 1989
 
BEND RESEARCH, INC. (2)
5,876,752 Use of interfacially-polymerized membranes in delivery devices 12 1993
5,698,220 Asymmetric membranes in delivery devices 37 1995
 
COLLEGIUM PHARMACEUTICAL, INC. (2)
2003/0035,839 Pharmaceutical composition for both intraoral and oral administration 23 2001
6,827,946 Compositions containing both sedative and non-sedative antihistamines 6 2001
 
E. R. Squibb & Sons, Inc. (2)
4,792,452 Controlled release formulation 101 1987
5,169,638 Buoyant controlled release powder formulation 96 1991
 
Nortec Development Associates, Inc. (2)
4,800,087 Taste-masked pharmaceutical compositions 104 1986
5,084,278 Taste-masked pharmaceutical compositions 104 1989
 
Richardson-Vicks Inc. (2)
4,996,047 Sustained release drug-resin complexes 71 1988
5,141,961 Process for solubilizing difficulty soluble pharmaceutical actives 21 1991
 
VALEANT INTERNATIONAL BERMUDA (2)
5,518,730 Biodegradable controlled release flash flow melt-spun delivery system 168 1992
5,869,098 Fast-dissolving comestible units formed under high-speed/high-pressure conditions 51 1997
 
ANALGESIC ASSOCIATES, A NY CORP. (1)
4,552,899 Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs 52 1984
 
ANDRX LABS, LLC (1)
5,837,379 Once daily pharmaceutical tablet having a unitary core 47 1997
 
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (1)
5,691,370 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2-adrenoceptor agonists 14 1996
 
CONCORDIA PHARMACEUTICALS, INC. (1)
5,763,449 Pleasant-tasting aqueous liquid composition of a bitter-tasting drug 18 1996
 
ELAN PHARMA INTERNATIONAL LIMITED (1)
4,952,402 Controlled release powder and process for its preparation 189 1988
 
FISONS CORPORATION (1)
4,959,219 Coating barriers comprising ethyl cellulose 22 1988
 
FOREST LABORATORIES, INC. (1)
4,369,172 Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose 224 1981
 
Gerhard Gergely (1)
5,834,019 Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system 7 1996
 
IBAH, INC. (1)
5,466,865 Neomorphic ibuprofen and methods of using same 5 1993
 
Jame Fine Chemicals, Inc. (1)
5,663,415 Process for preparing antihistamine tannates 32 1996
 
L'OREAL (1)
5,795,574 Use of an extract from a non-photosynthetic filamentous bacterium and composition containing it 17 1996
 
MAYNE PHARMA INTERNATIONAL PTY LTD (1)
5,807,579 Pseudoephedrine combination pharmaceutical compositions 43 1996
 
MEDE VA PHARMACEUTICALS MANUFACTURING INC. (1)
4,762,709 Liquid prolonged release pharmaceutical formulations containing ionic constituents 31 1986
 
MEDEVA CALIFORNIA, INC. (1)
4,650,807 Antihistaminic compositions and methods containing pyridine derivatives 8 1985
 
Menley & James Laboratories, Ltd. (1)
4,692,462 Compositions and method of controlling transdermal penetration of topical and systemic agents 26 1985
 
MERCK SHARP & DOHME CORP. (1)
5,314,697 Stable extended release oral dosage composition comprising loratadine and pseudoephedrine 37 1992
 
N.V. ORGANON (1)
5,662,936 Sugar-coated pharmaceutical dosage unit 5 1994
 
Plastic Dress-Up Co. (1)
5,895,663 Pseudoephedrine hydrochloride extended-release tablets 15 1997
 
PURDUE PHARMA L.P. (1)
4,834,985 Controlled release pharmaceutical composition 184 1987
 
R.P. SCHERER TECHNOLOGIES, INC. (1)
5,858,409 Hydrolyzed cellulose granulations for pharmaceuticals 38 1996
 
RANBAXY LABORATORIES LIMITED (1)
6,267,986 Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine 9 1999
 
SCHWARZ PHARMA, INC. (1)
4,576,645 Whipped gel composition 19 1984
 
SHAKER, GHASSAN I (1)
5,660,833 Anti-tussive composition 3 1996
 
SRCHEM, INCORPORATED (1)
5,288,503 Cryogel oral pharmaceutical composition containing therapeutic agent 78 1992
 
Sterling Drug Inc. (1)
4,181,719 Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates 13 1978
 
Taro Vit Industries, Ltd. (1)
5,881,926 Pharmaceutical compositions in semisolid form and a device for administration thereof 36 1993
 
TCF BANK SAVINGS FSB N/K/A TCF NATIONAL BANK (1)
5,126,145 Controlled release tablet containing water soluble medicament 105 1990
 
UNIVERSITY OF MASSACHUSETTS (1)
5,595,997 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine 32 1994
 
Other [Check patent profile for assignment information] (3)
4,777,170 Method to prevent and treat the signs and symptoms of motion sickness 22 1987
5,543,405 Composition and method for weight reduction and long term management of obesity 40 1994
5,859,060 Timed release tablet comprising naproxen and pseudoepherine 24 1997

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jul 10, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 10, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 10, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00